LONDON--(BUSINESS WIRE)--Nov. 7, 2003--Amersham (LSE, NYSE, OSE: AHM), a world leader in medical diagnostics and in life sciences, announces that Eli Lilly and Company (NYSE: LLY - News) has purchased an integrated suite of cellular screening technology and licenses to help in the identification of potential therapeutics in its drug discovery program.
In addition to the purchase of an IN Cell Analyzer 3000 high-throughput sub-cellular imaging system, Lilly has signed an agreement with Amersham for rights to Aequorea Victoria Green Fluorescent Protein (GFP). Furthermore, Lilly has secured rights to operate under BioImage's Redistribution(TM) patent portfolio for monitoring intracellular signalling pathways, including protein translocation.
Utilizing the advanced imaging quality and speed of the IN Cell Analyzer 3000 system in conjunction with the Aequorea Victoria GFP and Redistribution helps speed cellular screening capability and, ultimately, aid the discovery of new pharmaceuticals by examining disease-related targets in an informative biological context.
"We are delighted to be working with Lilly in this area," said Mike Evans, Vice President Marketing and Strategy, Discovery Systems at Amersham Biosciences, "Lilly's decision to utilize GFP and Redistributiontechnology together with the IN Cell Analyzer 3000 reflects the trend in the pharmaceutical industry towards generating biological inform ation earlier in the drug development process to speed up the time to market. We look forward to working closely with Lilly in the future."
"I am pleased that Lilly has chosen Redistribution to enhance its drug discovery program." said Dr. Patrik Dahlen, CEO of BioImage. "We are proud to have contributed with the Redistribution technology and look forward to its further utilization in drug discovery."
Lilly researches, develops, manufacturers and sells human therapeutics designed to treat a range of human diseases. Lilly has operations in 146 countries.
ends - Notes to Editors:
Following a series of strategic alliance deals with BioImage A/S, Columbia University and Invitrogen IP Holdings, Inc. (the successor to an agreement originally with Aurora Biosciences Corporation), Amersham Biosciences is able to offer the intellectual property rights necessary to utilize Aequorea victoria GFP. A further agreement with BioImage A/S has enabled Amersham's ability to license the Redistribution patent portfolio to Lilly.
Amersham plc (LSE.NYSE, OSE: AHM) is a world leader in medical diagnostics and in life sciences. Headquartered in the UK, the company had sales of GBP1.62 billion in 2002 and has over 10,000 employees worldwide. Its strategy is to build its position as a leading provider of products and technologies enabling disease to be better understood, diagnosed earlier and treated more effectively.
Amersham Biosciences, the life sciences business of Amersham, is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences' products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia.
Amersham - bringing vision to medical discovery
For additional information, visit the Amersham plc web site at www.amersham.com or the Amersham Biosciences web site at www.amershambiosciences.com
BioImage A/S uses its expertise in protein translocation technology - Redistribution - to discover drug candidates against known signalling targets that cannot be inhibited with absolute specificity by traditional means. The company's high-throughput cell-based translocation assays make these targets amenable to drug discovery. Drugs discovered using BioImage's technology should operate through a new mode of action that will demonstrate completely different selectivity profiles compared to traditional active-site inhibitors and are likely to produce fewer side effects. The company's novel approach to pathway screening offers exceptional target and drug discovery opportunities in most therapeutic areas. BioImage is presently working in the areas of inflammatory and cancers and are looking to commercialize drug candidates discovered in these programmes through collaborations with pharmaceutical and biotechnology companies. The trademarks BioImage and Redistribution used herein are owned by BioImage A/S, Denmark.
For more information please visit www.bioimage.com
Cautionary statement for purposes of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995
The Private Securities Litigation Reform Act of 1995 provides for a "safe harbor" for forward-looking statements. This press release contains certain forward-looking statements, which reflect the Company's views about future events and financial performance. The following important factors could cause actual results to differ materially from those projected or implied in any forward-looking statements:
i. Changes in demand for the products of Amersham plc worldwide or the markets for those products, as well as changes in management's expectation of the development of new markets and the timing of completion of various trials leading to the introduction of new products.
ii. Changes in the cost or supply of raw materials, changes in interest rates and the impact of competition; and
iii. Price controls and price reductions, fluctuations in exchange rates for foreign currencies, changes in governmental regulation, and the risk of loss of patents or trademarks.
Readers should also review the statements included in "Item 3. Key Information. D. Risk Factors" of the Company's Annual Report on Form 20-F for the year ended December 31, 2002, filed with the United States Securities and Exchange Commission (File No. 1-14710) for a discussion of additional factors or events which could cause actual results to differ materially from those projected or implied in any forward-looking statements.
The foregoing factors should not be construed as exhaustive. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on these forward-looking statements. In any event, these statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update or revise any of them, whether as a result of new information, future events or otherwise.
Amersham Biosciences: Media: Helen Petts Tel +44 1494 498068 or
Eric Rayvid, Evins Tel +1 212 688 8200 or
UK Investors: Alexandra Morris Tel +44 1494 542 051 or
Media: Dr. Graeme Holland Tel: +44 1494 542 115 or
Dr. Lynne Gailey Tel: +44 1494 542 050 or
US Investors and Media: Lucy Morrison Tel: +1 732 457 8092
Source: Amersham Biosciences